Cell therapy using your own immune cells for colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies an immune cell treatment made from your own blood cells to treat colorectal cancer that has spread or progressed. You may be eligible if you have stage III–IV disease that can be measured on scans and if standard treatments have not worked or couldn’t be tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 70 years old
- You have colorectal cancer that is stage III or IV
- You have at least one tumor spot that can be measured on scans (outside the brain)
- You’ve tried at least one or two standard treatments before, or they stopped working or couldn’t be tolerated
- Your doctor expects you can live at least 90 more days and that your major organs work well
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.
This trial tests a combination of immune cells (DC-CIK) and three cancer drugs (epaloliposide, vortexil, and regorafenib) as a third-line treatment for people with advanced colorectal cancer that has spread. It aims to see if this mix is safe and helps shrink tumors or slow the cancer's growth.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. It targets tumors with specific genetic markers (KRAS or NRAS G12D and HLA-A*11:01) to see if it can shrink or slow the cancer.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.